Literature DB >> 26385861

[TH-302: a new hypoxia-activated cytostatic agent in pancreatic cancer treatment].

Claudia Schmalz1, Jürgen Dunst2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26385861     DOI： 10.1007/s00066-015-0877-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  7 in total

Review 1.  Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.

Authors:  Jens Overgaard
Journal:  Radiother Oncol       Date:  2011-04-19       Impact factor: 6.280

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.

Authors:  Thomas Kuhnt; Arndt-Christian Mueller; Tanja Pelz; Gabriele Haensgen; Marc Bloching; Sabrina Koesling; Johannes Schubert; Juergen Dunst
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

4.  Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.

Authors:  Jens Bentzen; Kasper Toustrup; Jesper Grau Eriksen; Hanne Primdahl; Lisbeth Juhler Andersen; Jens Overgaard
Journal:  Acta Oncol       Date:  2015-01-28       Impact factor: 4.089

5.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

Authors:  J Overgaard; H S Hansen; M Overgaard; L Bastholt; A Berthelsen; L Specht; B Lindeløv; K Jørgensen
Journal:  Radiother Oncol       Date:  1998-02       Impact factor: 6.280

6.  Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

Authors:  Mitesh J Borad; Shantan G Reddy; Nathan Bahary; Hope E Uronis; Darren Sigal; Allen L Cohn; William R Schelman; Joe Stephenson; E Gabriela Chiorean; Peter J Rosen; Brian Ulrich; Tomislav Dragovich; Salvatore A Del Prete; Mark Rarick; Clarence Eng; Stew Kroll; David P Ryan
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

7.  Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors.

Authors:  J Overgaard
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.